- BAT’s adjusted operating profit for the financial year has met the estimated figures, achieving GBP12.47 billion against the estimated GBP12.56 billion.
- The company’s revenue for the year was GBP27.28 billion, slightly lower than the estimated GBP27.73 billion.
- For each share, the dividend declared was 235.5p.
- The adjusted earnings per share (EPS) stood at 375.6p, which was very close to the estimated 375.9p.
- The company’s performance has prompted 13 buy recommendations, 4 hold recommendations, and no sell recommendations.
A look at British American Tobacco Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
British American Tobacco is a well-established company that produces and sells various tobacco products, such as cigarettes, cigars, and roll-your-own tobacco. Based on the Smartkarma Smart Scores, the company has a positive long-term outlook, with high scores in the areas of value and dividend, indicating a strong financial performance and potential for good returns for investors.
The company also scores well in growth, showing potential for future expansion and profitability. However, its resilience score is lower, indicating some vulnerability to market changes and potential risks. Additionally, the company’s momentum score is moderate, suggesting that it may not be experiencing significant growth or decline in the short term.
Overall, British American Tobacco‘s strong scores in value, dividend, and growth demonstrate its potential for long-term success, but its lower scores in resilience and momentum should be considered when making investment decisions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
